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Background: Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in 
the United States. As there is systemic as well as local inflammation in COPD patients and evaluating the stage 
of the disease is not possible by spirometery alone, we evaluated High-Sensitivity C-reactive Protein (HS-CRP) 
in a group of COPD patients as an available and cost effective auxiliary marker in determining COPD stages. 
 
Methods: In a cross-sectional study in 160 COPD patients who were admitted for exacerbations in Razi Hospital 
in Rasht, Data on patients' demographic characteristics, pulmonary function test (PFT) and laboratory results 
consist of arterial blood gases and HSCRP levels were analyzed. 
 
Results: A significant positive correlation was seen between serum HSCRP level and stages of the disease (as 
GOLD criteria). There was a significant relationship between HSCRP level and patients' sex, BMI, and smoking 
history in a way that men and smokers showed higher and patients with normal BMI showed lower HSCRP lev-
els. The patients with higher PCO2 also showed a higher level of serum HSCRP. 
 
Conclusions: This survey supports the role of HSCRP as a simple auxiliary marker in staging and determining 
the prognosis of COPD for early management. 
 





Chronic obstructive pulmonary disease (COPD) is 
defined as a disease state characterized by airway lim-
itation that is not fully reversible, is usually progres-
sive and is associated with an abnormal inflammatory 
response of the lungs to inhaled noxious particles or 
gases.
1-3 In COPD, subsets of patients may have dom-
inant features of chronic bronchitis, emphysema, or 
asthma. The result is irreversible airflow obstruction. 
COPD is a disorder that causes a huge degree of hu-
man suffering and currently is the fourth leading 
cause of death in United States. Development of the 
20
th century included the widespread use of spirome-
try, recognition of airflow obstruction as a key factor 
in determining disabilityin COPD.
4-6  
Patients with COPD experience a systemic in-
flammation which can be assessed by measuring in-
flammatory mediators like C-reactive protein (CRP).
7 
Recently, High-Sensitivity C-reactive Protein (HS-
CRP) measuring methods have made it possible to 
assess this protein in lower levels of inflammation. 
Prognostic value of HS-CRP is proved in cardiovas-
cular diseases.
8 The cellular composition of the air-
way inflammation in COPD is predominately mediat-
ed by neutrophils. Macrophages also play an im-
portant role through macrophage-derived matrix met-
alloproteinase (MMPs). Mounting evidence supports 
that the dysregulation of apoptosis and defective 
clearance of apoptotic cells by macrophages play pre-
dominant role in airway inflammation.
9,10 
The aim of the present study was to assess HS-
CRP as a cost-effective auxiliary marker other than 
spirometery in determining severity of COPD and 
better control of disease prognosis in patients with 
exacerbations, and also explore the co-variants such 
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PCO2 in these patients. 
 
 
Materials and Methods 
 
This was a descriptive cross-sectional study which 
was performed on COPD patients who were referred 
to Respiratory Department of Razi Hospital, Guilan, 
North Province of Iran because of COPD acute exac-
erbation during 2008-2009. COPD patients whose 
diseases were diagnosed by specialists and confirmed 
by spirometery (as gold criteria) entered the survey. 
They were excluded if their diseases were not con-
firmed by FEV1/FVC<70% or FEV1/VCmax<70% in 
Pulmonary Function Test (PFT), or if they had a his-
tory of asthma, connective tissue disorders (e.g. 
Rheumatoid Arthritis, Systemic Lupus Erythemato-
sus, …), inflammatory diseases (e.g. Inflammatory 
Bowel Disease) or a known malignancy.  
Data were collected on patients’ demographic char-
acteristics, co-morbidities (hypertension, congestive 
heart failure, diabetes mellitus, Hyperlipidemia) by 
history, physical exam and echocardiography, smoking 
habits and number of exacerbations. The following 
laboratory tests were performed for all patients in the 
same lab: HS-CRP with the same kit at the beginning 
of admission; Arterial blood gases (e.g. PO2, PCO2); 
Pulmonary function tests (e.g. FEV1, FVC, 
FEV1/FVC), severity of disease that was determined 
by Gold Criteria and blood samples (for Hb, HCT).  
* HS-CRP was measured quantitavely by micro-
plateimmunoenzymometric assay and interpreted in 
the ranges of <3 mg/l (normal and low risk) and ≥3 
mg/l (high risk). Data were analyzed using descrip-
tive statistics (e.g percentage and mean) and compar-
ing means (e.g. Chi Square, T and Pearson's correla-





In this study, 160 known COPD patients (134 males 
and 26 females) with exacerbation were assessed. 
Baseline characteristics of patients were shown in 
Table 1. Their mean age (SD) of sample was 
65.19±10.66 years. Among the participants, 127 pa-
tients (79.4%) were smokers, 92 patients had at least 
one co-morbidity. Regarding severity of disease ac-
cording to gold criteria, one patient was in stage I, 34 
(21.3%) in stage II and most of them (125 patients) 
were in stage III and IV. Mean serum HS-CRP level 
was 11.65±15.03 mg/l. Among the samples, 54 
(33.8%) patients showed mild and 52 (32.5%) re-
vealed moderate hypoxemia (PO2 60-80 mmHg and 
40-60 mmHg respectively) and most of them (61.2%) 
showed PCO2≥45mmHg. The most common co-
morbidities were heart failure and hypertension 
(77.5% of all co-morbidities). 
 
Table 1: Baseline characteristics of the COPD pa-
tients and their relationship with HS-CRP
a. 
Variables
a Mean (SD)  P value
b
Age, year  65.19 (10.66)  0.318 
BMI 22.75  (4.97)  0.008 
Pack/year history in 
smokers 
48.11 (24.01)  0.189 
Number of exacer-
bations 
1.02 (1.18)  0.581 
PaO2 (mmHg)  65.64 (21.30)  0.772 
PaCO2 (mmHg)  52.21 (15.59)  0.011 
FEV1(% predicted)  36.83 (14.30)  0.0001 
Hb (g/dl)  13.01 (2.09)  0.53 
a Chi-square test was used to determine the relation-
ships 
bP value <0.05 considered as significant 
 
Also 31.3% of males and 34.6% of females showed 
anemia (HCT<39% in males and <36% in females). 
Men and smokers showed significantly higher lev-
els of HS-CRP (p=0.014 and p= 0.043, respectively). 
Of the factors in Table 1, patients’ BMI , PaCO2, and 
stage of disease (as gold criteria) showed significant 
association with HS-CRP level (p=0.008,  p=0.011, 
and  p=0.0001 respectively); but there was no rela-
tionship between age groups, amount of smoking 
(pack/year), any of the co-morbidities and number of 
exacerbations during last year and HS-CRP level.  
The relationship between BMI and HS-CRP level 
showed that patients with normal BMI (18.5-25 
kg/m
2) mostly had lower levels of serum HS-CRP 
while underweight and overweight patients tended to 
have high risk levels of HS-CRP (Figure 1). Of the 
factors in Table 2, PO2, mean of Hb and HCT did not 
show any correlation with HS-CRP level, but by in-
creasing PCO2 in Arterial Blood Gas, patients 
showed higher HS-CRP too. Table 2 shows Pearson’s 





The main finding of our study was that serum HS-
CRP level was significantly correlated to stage of dis-HsCRP in COPD exacerbation 
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ease (as gold criteria). Also we found a significant 
relationship between patients' serum HS-CRP level 
and their gender, BMI, smoking habits and PaCO2 in 
exacerbation state. In the present study, more males 
showed high risk levels of HS-CRP than females, 
similar to Breyer's study (2005-2007)
11 which showed 
an increased likelihood for highly elevated CRP in 
males.Overall, considering this fact that in the present 
study COPD gold stages were significantly higher in 
males, maybe the reason of higher CRP levels in men 
was higher stages of disease in these patients.  
Although it seems that COPD patients experience 
some degrees of metabolic changes and muscle wast-
ing, and this fact is associated with higher levels of 
inflammatory markers and hypermetabolic state, in 
this study and some similar investigations overweight 
and obese patients (measured by BMI) showed higher 
levels of CRP (as an inflammatory marker) than nor-
mal weight patients. In a study by Attaran et al. 
(2008) in Mashhad, there was no relationship be-
tween BMI and HS-CRP level.
12 But in Juan de 
Torres  et al. study (2008) in Spain, patients with 
higher CRP levels showed a higher BMI.
13 Also in 
Breyer et al.'s study,
11 obese patients showed higher 
CRP levels than normal weight patients. They also 
analyzed Fat Free Mass Index in these patients and 
did not find any relationship between CRP and Fat 
Free Mass Index. So they did not get to a definite 
conclusion. In de torress et al.'s study (2002-2004), 
BMI was correlated directly with CRP and they con-
cluded that inflammatory markers such as TNF-α and 
CRP, had different behavior, relating to malnutrition 
or perhaps reflecting depletion of different compo-
nents (FFMI versus fat mass, respectively).
14 
The novel finding of the present study was that un-
derweight patients showed higher HS-CRP levels than 
normal weight patients (that shows muscle wasting ef-
fects of systemic inflammation) as well as obese and 
overweight patients. Although in 3 BMI groups, majori-
ty of patients showed high risk of CRP levels, patients 
with normal BMI as Chi-square analysis were most like-
ly to have low risk HS-CRP levels (p=0.008). 
Increased CRP levels in obese COPD patients, 

















Fig. 1: BMI and HS-CRP relationship in COPD patients 
 
 
Table 2: Correlations between different variables and HS-CRP in COPD patients. 
Variables Pearson's  correlation(r) P value
a 
PaO2 (mmHg)  0.023  0.772 
PaCO2 (mmHg)  +0.201  0.011 
Hb (g/dl)  0.050  0.53 
FEV1(% predicted)   -0.392  0.0001 
aP value <0.05 was considered significant Alavi et al. 
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in part be explained by the fact that increased adipose 
tissue induced increased levels of adipocytokynes 
which in turn may stimulate production of CRP in the 
liver. Indeed, IL-6 and TNF-α were shown to stimu-
late the production of CRP through facilitating 
hepatocytes.
11 More studies are needed to help re-
solve the controversial findings. 
In the present study, more percentage of smokers 
showed high risk levels of HS-CRP (p=0.043), but 
there was no significant difference in Pack/Year histo-
ry of patients between different HS-CRP levels 
(p=0.189). de Torres et al. in two different studies did 
not show any significant relationship between amount 
of smoking and HS-CRP levels, although smokers 
showed higher levels of HS-CRP.
13,14 Halvani et al. 
(2006) also did not find any significant relationship in 
HS-CRP level between smokers and non-smokers. In 
their opinion, although smoking had a role in initiation 
of inflammatory process in COPD patients, it was not 
the leading cause of increased inflammatory markers.
15 
It is now widely accepted that smoking is the main 
risk factor for reduced pulmonary function in COPD. 
Compounds of tobacco smoke also penetrated into the 
blood stream, and were associated with a higher prev-
alence of coronary artery disease, endothelial dys-
function, and high serum concentrations of markers 
of systemic inflammation. High CRP concentrations 
may reflect the effects of smoking, but this observa-
tion that changes in CRP concentrations were associ-
ated with FEV1 decline in those who had never 
smoked can imply this fact that this association may 
not be due to smoking.
16 It should be noticed that not 
all cases develop inflammatory reaction following 
smoking and only some of them would show this reac-
tion which can be due to genetic differences.
17 In the 
present study, the effect of other environmental factors 
which can act similar to smoking was not analyzed. 
In the current study we did not find significantly 
higher HS-CRP levels in those who had one or more 
co morbidities (Coronary Artery Diseases, Conges-
tive Heart Failure, Hypertension, and Diabetes Melli-
tus) or had one or more exacerbation histories during 
the last year. In the literature, there are strong argu-
ments for CRP increasing thrombotic risk and cardio-
vascular deaths.
9 But the findings of our study did not 
support this fact. Donaldson et al.
18 in their study 
showed no higher prevalence of ischemic heart dis-
ease in participants who had a COPD outcome than 
those free of an event. Also in their study, none of the 
inflammatory markers were associated with a greater 
prevalence of heart diseases. Torres et al. (2004) did 
not find any significant relationship between CRP 
levels and cardiovascular risk factors and diseases 
too.
14 Maybe such as some other researches, we can 
say that CRP is a strong predictor of COPD out-
comes, independent of cardiovascular diseases.  
We should take it into account that we did not 
matched patients by drugs which they used as statins 
and we also did not actively assess cardiovascular 
diseases and risk factors except Congestive Heart 
Failure which was confirmed by echocardiography. 
Others were diagnosed by history and physical exam 
and patients were not followed for future outcomes. 
Another strange findings of the present study just 
like Halvani et al. and Pinto-Plata et al.'s studies
15,17 
was not a relationship between number of exacerba-
tions during last year and HS-CRP level. We did not 
have any justification for this finding. Maybe it is due 
to some limitations as low sample size, just studying 
exacerbations during a single year and not consider-
ing different cultural states of patients. 
Among laboratory findings we found significant 
relationship between HS-CRP and PaCO2 
(p<0.0001) but not about PaO2 and Hb. Attaran et 
al.,
12 similarly found a positive correlation between 
HS-CRP and PaCO2 and no relationship was noticed 
between HS-CRP and PaO2 in patients with COPD 
due to toxicity with sulfur mustard. Breyer et al. did 
not find any significant difference in PaO2 between 
different levels of CRP.
11 The key point comes from 
Bircan et al.’s study which found negative correla-
tion between PaO2 and HS-CRP in control group 
and patient with stable COPD but not in patients 
with exacerbation.
19 As we see in our study and 
Bircan  et al.’s study, PaO2 was not a valuable 
measurement while exacerbations and perhaps Pa-
CO2 was a better tool for making decisions. Maybe 
the reason is that these patients mostly are in respira-
tory distress and immediately inhale considerable 
amount of O2 in the beginning of admission and 
maybe this is just a bias due to different factors 
which can interfere in final result of an ABG test. 
The main finding of the current study was the 
correlation between FEV1% (stage of disease) and 
HS-CRP level in COPD patients with exacerbation. 
In Halvani et al.’s study, serum CRP level was signif-
icantly higher in COPD patients.
15  de Torres et al. 
(2004) showed a correlation between CRP and FEV1 
in stable COPD patients.
14 Shaaban et al. in a cross-
sectional analysis (2001) found a significant relation-
ship between FEV1% and CRP, although longitudinal 
analysis didn’t support it.
16 Rezayitalab et al. similar-HsCRP in COPD exacerbation 
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ly found a negative correlation (r= 0.341) between 
CRP and HSCRP.
20 Also Bircan et al. got to a nega-
tive correlation between these two factors (r=0.417).
19 
We found a negative correlation between HS-CRP 
and FEV1% in exacerbation too (r=0.392).  
The reasons for the inverse association between 
systemic inflammation and reduced pulmonary func-
tion are unclear but several mechanisms maybe in-
volved. First, reduced lung function may be responsi-
ble for systemic inflammation. Like hepatocytes, in-
flammatory lung or pulmonary epithelial cells, have 
been shown to express CRP and IL-6. An alternative 
mechanism–reverse causation- cannot be excluded. 
High levels of cytokines and acute phase reactants in 
peripheral circulation maybe a cause rather than a 
consequence of poor lung function.
16  
Considering CRP as a systemic inflammatory 
marker and systemic inflammation as an important 
factor in determining outcomes of COPD patients, and 
increase in higher stages, it seems that this marker can 
be useful as an auxiliary marker other than Pulmonary 
Function Test in follow up of patients and assessing 
their status and effects of treatments. 
Limitations of the present study were low sample 
size, not analyzing drugs including statins and corti-
costeroids, and not having a matched control group. 
Totally, the current study supports a relationship be-
tween HS-CRP as an inflammatory marker and stage 
of COPD (as gold criteria) and PaCO2 and also im-
plies that increasing inflammation in higher stages is 
not due to cardiovascular diseases and is due to the 
disease itself. This study confirms that HS-CRP in-
creases following smoking but there is a question 
whether smoking is the main cause of increase in 
CRP level in the patients or not and this study sup-
ports the role of obesity in increase of inflammation 
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